JP Morgan Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $36

Benzinga Newsdesk www.benzinga.com Negative 87.0%

Neg 87% Neu 0% Pos 0%

JP Morgan analyst Anupam Rama downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Overweight to Neutral and lowers the price target from $80 to $36.